Updated use of aminoquinolines for the treatment of COVID 19

Authors

  • Héctor Hugo Arredondo-Niño <p>Instituto Mexicano del Seguro Social, Hospital General de Subzona No.&nbsp;17, Departamento de Medicina Interna. Miguel Alem&aacute;n, Tamaulipas</p> http://orcid.org/0000-0003-4037-9214

Keywords:

Aminoquinolines, COVID-19

Abstract

Due to the current pandemic produced by the SARS‑CoV‑2, there has been a scientific race in order to find an appropriate treatment and prophylaxis for patients with COVID-19. Multiple studies in the literature have shown that chloroquine and hydroxychloroquine inhibits the virus in vitro. However the majority of the in vivo data comes from observational studies, some of these with severe flaws in their study design. It’s important to make conclusions based on the results of the randomized controlled trials that are underway.

Downloads

Download data is not yet available.

References

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269‑71. doi: 10.1038/s41422-020-0282-0

 

Wellems TE, Plowe CV. Chloroquine‐resistant Malaria. J Infect Dis. 2001;184(6):770‑6. doi: 10.1086/322858

 

Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938

 

Jang C-H, Choi J-H, Byun M-S, Jue D-M. Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology. 2006;45(6):703‑10. doi: 10.1093/rheumatology/kei282

 

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal. 2005;2(1):69. doi: 10.1186/1743-422X-2-69

 

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517‑25. doi: 10.1056/NEJMoa2016638

 

Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;S0140-6736(20):31180‑6. doi: 10.1016/S0140-6736(20)31180-6

 

Joseph A. WHO resumes hydroxychloroquine study for Covid-19 [Internet]. STAT. [consultado el 9 de junio de 2020]. [aprox. 2 pantallas]. Disponible en: https://www.statnews.com/2020/06/03/who-resuming-hydroxychloroquine-study-for-covid-19/

 

Davey M, Kirchgaessner S, Boseley S. Surgisphere: governments and WHO changed Covid-19 policy based on suspect data from tiny US company [Internet]. The Guardian. [Actualizado 3 Jun 2020; citado 9 Jun 2020]. [aprox. 4 pantallas]. Disponible en:https://www.theguardian.com/world/2020/jun/03/covid-19-surgisphere-who-world-health-organization-hydroxychloroquine

 

Mehra MR, Ruschitzka F, Patel AN. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820, doi: 10.1016/S0140-6736(20)31324-6

Downloads

Published

2021-10-15

Issue

Vol. 58 No. Suplemento 2 (2020)

Section

Opinion Articles

License

Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.